Key clinical point: A small case series suggests Epstein Barr virus (EBV) status may be a useful prognostic marker for patients with aggressive B-cell non-Hodgkin lymphomas (B-NHL) in the nasopharynx area.
Major finding: After 2- and 5-years of follow-up, the survival rates for EBV-negative patients were 100% and 83%, respectively. Patients who were EBV-positive died within 1 year of diagnosis.
Study details: A retrospective case series of 53 patients with aggressive B-NHL, including 48 patients with diffuse large B-cell lymphoma.
Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.
Chen PH et al. Ann Diagn Pathol. 2019 Aug;41:129-35.